The article discusses the perceived risks and benefits of choosing a large Contract Research Organization (CRO) for complex trials. It challenges the assumption that larger CROs automatically offer lower risk, pointing out that their scale can sometimes lead to inefficiencies and a lack of personalized attention. The piece emphasizes the importance of thoroughly evaluating a CRO’s true capabilities, regardless of its size, to ensure the best fit for a clinical trial’s specific needs.
